Nav: Home

Recurring infections could lead to delayed bladder or kidney cancer diagnosis

February 13, 2019

Women with bladder or kidney cancer may lose out on a prompt diagnosis if they are already being regularly treated for recurring urinary tract infections (UTIs), according to new research presented at Cancer Research UK's Early Diagnosis Conference in Birmingham today (Wednesday).

The research suggests this may be because a person prone to infection is assumed to be suffering from yet another UTI rather than being investigated for potential cancer.

The analysis of 24 studies and more than 100,000 people found that up to two thirds with blood in their urine - a UTI symptom and a possible sign of cancer - had no check-up in the six months after their initial visit to a doctor.

UTIs are more common in women than in men. Although UTIs are not directly related to cancer, failing to get recurring infections or blood in the urine checked by a doctor could lead to a delayed cancer diagnosis, particularly among older women.*

The researchers think that developing electronic tools within existing GP computer systems to flag-up patients with ongoing symptoms, or recurring UTIs in older people, could help GPs to identify who may need further investigations or a referral to a urologist.

Dr Yin Zhou, lead author from the University of Cambridge, said: "Detecting cancer early is vital for giving patients the best treatment options and improving survival. This research is an important step towards improving our understanding of why some people are diagnosed later than others.

"Although UTIs are the second most common condition that GPs are prescribing antibiotics for, in some people, symptoms of a UTI may be masking symptoms of bladder or kidney cancer. Only a small number of patients with persistent symptoms and recurring UTIs will go on to develop cancer but it's important that we don't miss them. The next step will be to find a way to detect these patients earlier."

More than 10,500 people are diagnosed with kidney cancer and around 8,500 people are diagnosed with bladder cancer each year in the England. Of those, around 3,400 are diagnosed with late stage kidney cancer and 1,800 with late stage bladder cancer.

When caught early at stage I, kidney cancer patients' five-year survival is seven times greater than when diagnosed at stage IV.** And more than twice as many patients survive bladder cancer for at least a year when diagnosed with stage I disease compared with stage IV.***

Sara Hiom, director of early diagnosis at Cancer Research UK, said: "Early stage cancers may not always display obvious symptoms, but this research highlights the importance of tracking persistent symptoms and ensuring ongoing problems are not ignored. We continue to use the latest evidence to find new ways to support GPs and practices to ensure all patients receive an accurate diagnosis as swiftly as possible - this can make all the difference to their experience and outcome.

Dr Richard Roope, Cancer Research UK's GP expert, said: "GPs see many patients with symptoms suggestive of a urinary infection - thankfully the vast majority will never go on to develop kidney or bladder cancer. But this research shines a light on the importance of taking a step back to consider what might be causing any recurrence of symptoms, rather than assuming the diagnosis is the same as it has been before.

"There's no easy way to know which patients need to be referred or seen again. All GPs want the best for their patients so research like this, highlighting where improvements need to be made, such as arranging a review, is very useful."****
-end-


Cancer Research UK

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Setbacks
Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".